Nilutamide

Nilutamide (INN, USAN, BAN) (brand names Nilandron (US), Anandron (CA)) is a synthetic, non-steroidal, pure antiandrogen used in the treatment of advanced-stage (metastatic) prostate cancer. It was developed by Roussel, introduced in 1987, and was the second non-steroidal antiandrogen to be marketed after flutamide. Nilutamide acts as a potent and selective competitive silent antagonist of the androgen receptor (AR), which prevents testosterone and other androgens from activating the AR. Because most prostate cancer cells rely on activation of the AR for growth and survival, nilutamide can extend life in men with prostate cancer.